3.5 ML evolocumab 120 MG/ML Cartridge [Repatha] — RxCUI 1801322
RxNorm drug concept · Semantic branded drug
RxCUI 1801322
Semantic branded drug · SBD
● Current RxNorm concept 4 FDA products
7 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1801322
Official name3.5 ML evolocumab 120 MG/ML Cartridge [Repatha]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as3.5 ML Repatha 120 MG/ML Cartridge; Repatha 420 MG in 3.5 ML Cartridge; Repatha 420 MG per 3.5 ML Cartridge
FDA products mapped4
Package NDCs mapped7
Reported Medicaid activity (SDUD)262,375 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Evolocumab Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Repatha is used for two main purposes. First, it lowers LDL ('bad') cholesterol — it's prescribed for adults with high cholesterol and for adults and kids aged 10 and older with an...
- You inject Repatha under the skin — into your abdomen, thigh, or upper arm. The most important things to remember: let it warm up to room temperature for at least 30 minutes before...
- How do I give myself this injection, and does it hurt?
- The most common ones are pretty mild — cold symptoms, upper respiratory infections, flu, back pain, and occasional muscle aches. These usually aren't a reason to stop. What you do...
🕸️ Concept Web — How 3.5 ML evolocumab 120 MG/ML Cartridge [Repatha] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
3.5 ML evolocumab 120 MG/ML Cartridge [Repatha]
RxCUI 1801322 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Evolocumab
1665684IN
-
Evolocumab
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Repatha
1665896BN
-
Repatha
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Evolocumab Cartridge
1801318SCDF -
Evolocumab Injectable Product
1665893SCDG -
Evolocumab Cartridge [Repatha]
1801321SBDF -
Repatha Injectable Product
1665899SBDG -
Cartridge
1649572DF -
Injectable Product
1151126DFG
-
Evolocumab Cartridge
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
3.5 ML evolocumab 120 MG/ML Cartridge
1801319SCD -
Evolocumab 120 MG/ML
1801317SCDC -
Evolocumab 120 MG/ML [Repatha]
1801320SBDC
-
3.5 ML evolocumab 120 MG/ML Cartridge
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
3.5 ML evolocumab 120 MG/ML Cartridge
SCD · 1801319 -
Evolocumab 120 MG/ML
SCDC · 1801317 -
Evolocumab Cartridge
SCDF · 1801318 -
Evolocumab Injectable Product
SCDG · 1665893
Brand-Name Concepts
-
Evolocumab 120 MG/ML [Repatha]
SBDC · 1801320 -
Evolocumab Cartridge [Repatha]
SBDF · 1801321 -
Repatha Injectable Product
SBDG · 1665899 -
Repatha
BN · 1665896
📦 FDA Products & Package NDCs
4 products · 7 package NDCs
7 package NDCs map to RxCUI 1801322 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 72511-0393-01 | 1 SYRINGE in 1 CARTON (72511-393-01) / 1 mL in 1 SYRINGE | REPATHA | Amgen USA Inc. | 2024-11-24 |
| 72511-0393-02 | 2 SYRINGE in 1 CARTON (72511-393-02) / 1 mL in 1 SYRINGE | REPATHA | Amgen USA Inc. | 2024-11-24 |
| 72511-0393-96 | 1 SYRINGE in 1 CARTON (72511-393-96) / 1 mL in 1 SYRINGE | REPATHA | Amgen USA Inc. | 2024-11-24 |
| 72511-0501-01 | 1 SYRINGE in 1 CARTON (72511-501-01) / 1 mL in 1 SYRINGE | REPATHA | Amgen USA Inc. | 2024-11-24 |
| 72511-0750-01 | 1 SYRINGE in 1 CARTON (72511-750-01) / 1 mL in 1 SYRINGE | REPATHA | Amgen USA Inc. | 2018-10-09 |
| 72511-0760-02 | 2 SYRINGE in 1 CARTON (72511-760-02) / 1 mL in 1 SYRINGE (7... | REPATHA | Amgen USA Inc. | 2018-10-09 |
| 72511-0760-91 | 1 SYRINGE in 1 CARTON (72511-760-91) / 1 mL in 1 SYRINGE | REPATHA | Amgen USA Inc. | 2022-06-01 |
Observed labelers:
Amgen USA Inc. (7)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$281.8590
Range $281.6970–$282.0210
· middle 50% $281.6970–$282.0210
· 4 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.